Warning / Disclaimer and Cautionary Statements
This document and the results conference call (including the Q&A) may contain forward-looking statements and information (hereinafter referred to as "Statements") relating to ATRYS HEALTH, S.A. or the ATRYS Group (hereinafter referred to as "ATRYS", the "Company" or the "Group"). These statements may include financial projections and estimates with assumptions, statements regarding plans, objectives, and expectations that may relate to various matters, including, but not limited to, the customer base and its evolution, the growth of the various lines of business, market share, the results of the company and other aspects relating to the activity and situation of the company.
The forward-looking statements or forecasts contained in this document may be identified, in certain cases, by the use of words such as "expects", "anticipates", "intends", "believes" or similar language, or their corresponding negative form, or by the predictive nature of matters relating to strategies or plans or intentions. These forward-looking statements or forecasts reflect the views of ATRYS with respect to future events and are not, by their nature, guarantees of future performance and are subject to risks and uncertainties that could cause actual developments and results to differ materially from those expressed in such intentions, expectations or forecasts. Such risks and uncertainties include those identified in the documents with more complete information filed by ATRYS with the various supervisory bodies of the securities markets on which its shares are listed, and in particular with the Spanish Securities Market Commission (CNMV).
Except to the extent required by applicable law, ATRYS undertakes no obligation to publicly update the outcome of any revisions it may make to these statements to conform to events or circumstances after the date hereof, including, without limitation, changes in the Company's business, business development strategy or any other circumstances that may arise. This document may contain summary financial information, non-GAAP or unaudited information. The information contained herein should be read as a whole and is subject to all publicly available information about the Company, including, where applicable, other documents issued by the Company containing more complete information.
Finally, it is noted that neither this document nor anything contained herein constitutes an offer to buy, sell or exchange, or a solicitation of an offer to buy, sell or exchange any securities, or a recommendation or advice in respect of any securities
Atrys, 360º Health Services
We are a global healthcare provider offering innovative and personalised solutions for each patient. By 2024 we will have performed+ 9 million medical procedures (+18.5% vs. 2023).
Business
Areas ACTIVITY
2024
% Revenues Monitoring the health of 1M people.
200 care centres
+8.4M Telediagnostics4 Anatomy Labs
Pathology and Genetics
6 Centres Nuclear MedicineClinical trials
Management of 46 oncology services3 radiotherapy centres
Clinical trials
GEOGRAPHICAL PRESENCE
Spain, Portugal, Chile, Colombia, Peru, Brazil and Mexico
Main activity figures
With our more than 1,000 specialist doctors, we contribute to improving access to healthcare by offering innovative and precision medicine.
Guidance 2024
Turnover Evolution
Figures in EUR million.
7,3 11
2018 2019
202
212,7
20,8
2020
2023
158
107
2021
2022
2024
Financial years 2021/2022/2023 exclude Conversia and Atrys Switzerland. (APM) See definitions of alternative performance measures in Annex II.
2024 Guidance
222
Key financial figures
Solid growth in the main financial aggregates.
Turnover
Gross Margin (APM)
212,7
EBITDA (APM)
201,5
+5,5%
137,2
+2,0%
140
35,6
+15,7%
41,2
2023
2024
2023
2024
2023
2024
Adjusted EBITDA (APM)
CAPEX (APM)
Adjusted CFO (APM)
42,5
+13,8%
2023
Figures in millions of euros.
48,5
2024
(APM) See definitions of alternative performance measures in Annex II.
(13,1)
-0,1%
2023
(13,1)
2024
29,4
+20,1%
35,3
2023
2024
Prevention
Revenue growth of 4.4%.
Increase in healthcare activity by more than 3%. 11.8% increase in technical reports.
Growth of 9% in average customer ticket. Improved customer renewal rate by 2%.
Improved productivity and efficiency:
Optimisation of the network of centres: 3.4% reduction in installation and structure costs.
Implementation of a treasury tool that automates monitoring and control.
Automation of the technical activity that cross-selling. New tools for self-management: Client area, self-citation and worker App.
79,3
+4,4%
82,8
Gross Margin 2024:
96,0%
EBITDA margin Adj. 2024:
22,1%
2023
2024
Medical examinations Care centres Technical reports
+375K
210
+570K
Employee training TrainingCentres Clients
+220K
100
+48K
Diagnosis
Constant FX revenue growth of 9.2%.
33% increase in laboratory activity. Ramp up laboratory in Madrid with activity levels as planned and strong increase in genetics activity in Spain and Portugal.
Increase in tele-diagnostics +4.2%, excluding exchange rate effect +12.6%. Growth in business in Spain of +26.7%. Introduction of new business lines in Chile (management of waiting lists and pathology).
Clinical trials in nuclear medicine in diseases neurodegenerative and oncological diseases.
Improved productivity and efficiency:
Investment in genetics and pathology laboratories to increase competitiveness and efficiency. Implementation of savings and efficiency measures in OPEX.
AI tools.
Turnover at constant
66,9
9,2%
+3,5%
64,7
Gross Margin 2024:
53,1%
EBITDA margin Adj. 2024:
2023
2024
35,6%
Oncology
Revenue growth of 9.5%.
Opening of two centres in Spain and Mexico (Viamed Santa
Elena and Altavista).
Expansion of current portfolio and increase of customers in
Spain, Portugal and Mexico (60% of revenue growth).
Clinical trials in patient recruitment phase in Mexico and
Spain.
Opening of drug mixtures center in Mexico.
New partnership with AXA Keralty in Mexico. One centre already in operation and two more planned for opening in 2025.
Completion of the start-up process for the Valdebebas
Hospital radiotherapy unit (commencement of activity in June 2025).
Improved productivity and efficiency:
Implementation of efficiency measures and OPEX
+9,5%
63,0
57,5
Gross Margin 2024:
39,7%
EBITDA margin Adj. 2024:
20,9%
2023
2024
Key figures for the financial year 2024
Gross margin evolution (MAR) 2024
The change in the weight of the business areas in the Gross Margin mix explains why the Gross Margin will decrease from 68.1% to 65.5% in 2024.
Isolating the impact of the change in the weight of the business areas in the composition of the Gross Margin, the Gross Margin would have improved by +0.3% in 2024 compared to 2023.
As a result, the gross margin on revenues will increase from 68.1% in 2023 to 65.8% in 2024.
68,1%
(0,3)%
(0,6)%
(0,8)%
(0,9)%
65,5%
0,3%
65,8%
(%)
Gross margin 2023
Less weight in the Mix of the prevention area Less weight in the Mix of the Smart Data area
Greater weight in the
Mix of the Medical Oncology Mexico area.
Greater weight in the Mix of the Medical Oncology area Spain
(%)
Gross Margin 2024 due to changes in revenue mix Improvement in the Gross Margin of the businesses in the financial year 2024
(%)
Gross Margin 2024